Stay updated with breaking news from Published March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
As ketamine is becoming an increasingly popular treatment method for depression, we speak to an MD about administering ketamine in a medical clinic.
Researchers characterized patterns of global fatigue in patients treated for breast cancer.
Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does